Media
News & Events
WHO report on the public health response to dementia
The World Health Organization has published a "Global status report on the public health response to dementia" where it takes stock of actions driven by Member States, WHO and civil society since the adoption of the global action plan, identifies barriers to its implementation especially in light of the COVID-19 pandemic, and highlights areas where urgent, accelerated action is required.
A brighter future for Alzheimer's?
Asceneuron’s unique approach to treat Alzheimer’s disease featured by our CEO Dirk Beher in series of interviews with industry leaders on the future of Alzheimer's disease drug development.
Asceneuron awarded by the Alzheimer’s Drug Discovery Foundation
Asceneuron Receives USD 2.2 Million Award from the Alzheimer’s Drug Discovery Foundation
“A bright future for CNS and Alzheimer’s?”
Read the interview of our CEO Dirk Beher in Pharmaphorum.
Asceneuron proudly sponsors Atypical Parkinsonian Syndromes Workshop
As part of its commitment to neurodegenerative disease research and development, Asceneuron proudly sponsors the Atypical Parkinsonian Syndromes Workshop organised by the International Parkinson and Movement Disorder Society (MDS) in May 17-18, 2019 in Munich, Germany.
Interview of Dirk Beher, CEO & Founder, at the Biotech Showcase
Dirk Beher, CEO & Founder, was interviewed by Mike Ward (Scrip Pharma Intelligence) at the Biotech Showcase in San Francisco last week.
Asceneuron to present at the European Life Sciences CEO Forum
Our CEO Dirk Beher will be presenter and panellist at the 11th Annual European Life Sciences CEO Forum & Exhibition, February 26th-27th 2018, in Zurich.
"Treating Tau: Finally, Clinical Candidates Are Stepping into the Ring"
Read a detailed conference report on our clinical tau modifier presented at AD/PD 2017
Asceneuron is awarded Alzheimer’s Drug Discovery Foundation Grant
Alzheimer’s Drug Discovery Foundation (ADDF) awarded a USD 325,000 grant to support the development of Asceneuron’s tau modulators.